Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Motzer, Robert J.; Jonasch, Eric; Agarwal, Neeraj; Bhayani, Sam B.; Bro, William P.; Chang, Sam S.; Choueiri, Toni K.; Costello, Brian A.; Derweesh, Ithaar; Fishman, Mayer; Gallagher, Thomas H.; Gore, John L.; Hancock, Steven; Harrison, Michael R.; Kim, Won; Kyriakopoulos, Christos E.; LaGrange, Chad A.; Lam, Elaine T.; Lau, Clayton; Michaelson, M. Dror; Olencki, Thomas; Pierorazio, Phillip M.; Plimack, Elizabeth R.; Redman, Bruce G.; Shuch, Brian; Somer, Brad; Sonpavde, Guru; Sosman, Jeffrey A.; Dwyer, Mary A.; Kumar, Rashmi

doi:10.6004/jnccn.2017.0100

Cited by 516 publications

(548 citation statements)

References 183 publications

(245 reference statements)

Supporting

Mentioning

516

Contrasting

Unclassified

Order By: Relevance

“…This underestimation could be due to the following causes: 1) asymptomatic patients were unable to be assessed at initial diagnosis, and 2) the patients who developed BM later in their disease course were not recorded in the SEER database. The current guidelines only recommend bone imaging in symptomatic patients or in those with an unusual alkaline phosphatase level 11,12. Thus, a study assessing the risk factors for BM in RCC patients is necessary.…”

Section: Discussionmentioning

confidence: 99%

Incidence of bone metastasis and factors contributing to its development and prognosis in newly diagnosed renal cell carcinoma: a population-based study

Guo

Zhang

Guo

et al. 2018

CMAR

View full text Add to dashboard Cite

PurposeThe purpose of this study was to assess the incidence of and the risk factors and prognostic factors for bone metastasis (BM) in initial metastatic renal cell carcinoma (RCC) based on a large population analysis.Patients and methodsData were obtained for a total of 45,824 RCC patients recorded in the database of the Surveillance, Epidemiology, and End Results program of the National Cancer Institute between 2010 and 2014. Multivariate logistic and Cox regression analyses were used to identify the risk factors and prognostic factors associated with BM in RCC patients. Kaplan–Meier analysis was used to estimate the overall survival of RCC patients, and the difference between the survival curves was tested by log-rank tests.ResultsA total of 1,509 (3.29%) patients were diagnosed with bone metastases at initial diagnosis. Male gender, higher T stage, lymph node involvement, poor tumor grade, presence of lung, liver, and brain metastases, and the collecting duct type of RCC were positively associated with BM occurrence. The median survival time for RCC patients with bone metastases was 12.0 (95% confidence interval [CI]: 10.69–13.31) months, and the survival time for those with collecting duct, clear-cell, papillary, and chromophobe subtypes of RCC were 3 (95% CI: 0.23–5.77), 13 (95% CI: 11.60–14.40), 8 (95% CI: 5.09–10.91), and 11 (95% CI: 5.02–16.98) months; these differences were significantly different (P<0.01). Older age, higher T stage, lymph node involvement, poor tumor grade, the presence of lung, liver, and brain metastases, collecting duct RCC, and the absence of surgical treatments were the factors associated with worse prognoses.ConclusionBM was highly prevalent and significantly decreased the survival rate of RCC patients. A number of factors associated with the development and prognosis of BM were identified, and these insights provide preventive guidelines for screening and treatment of BM in RCC patients

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of bone metastasis and factors contributing to its development and prognosis in newly diagnosed renal cell carcinoma: a population-based study

Guo

Zhang

Guo

et al. 2018

CMAR

View full text Add to dashboard Cite

show abstract

“…This would reflect current guidelines by the National Comprehensive Cancer Network that recommend first-line treatment for stage IV clear-cell RCC with high-dose IL-2 only in those patients with "excellent performance status and normal organ function." 20 We found that some independent factors did reflect these requirements. Younger patients and those who had undergone cytoreductive nephrectomy were more likely to undergo immunotherapy than their older counterparts and those with an untreated primary tumor.…”

Section: Commentmentioning

confidence: 93%

Trends of Systemic Therapy Use for Renal Cell Carcinoma in the United States

Ferry

Minnillo

Maurice

et al. 2015

Urology

View full text Add to dashboard Cite

“…Once clinical T1 stage ccRCC has been identified, clinicians are faced with various treatment options ranging from surgical resection to non-surgical approaches such as cryoablation, radiofrequency ablation, and active surveillance, which are deemed to be particularly appropriate for patients of older age, harboring a single kidney, or those who have comorbidities and/or are reluctant to undergo a major surgery [[5], [6], [7]]. These clinical guidelines on the management of renal masses have been accepted by the American Urological Association, European Association of Urology, and National Comprehensive Cancer Network [[6], [7], [8]].…”

Section: Introductionmentioning

confidence: 99%

Risk Prediction Tool for Aggressive Tumors in Clinical T1 Stage Clear Cell Renal Cell Carcinoma Using Molecular Biomarkers

Park

Lee

Cho

et al. 2019

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

Some early-stage clear cell renal cell carcinomas (ccRCCs) of ≤7 cm are associated with a poor clinical outcome. In this study, we investigated molecular biomarkers associated with aggressive clinical T1 stage ccRCCs of ≤7 cm, which were used to develop a risk prediction tool toward guiding the decision of treatment. Among 1069 nephrectomies performed for ccRCC of ≤7 cm conducted between January 2008 and December 2014, 177 cases with available formalin-fixed paraffin-embedded tissue were evaluated. An aggressive tumor was defined as a tumor exhibiting synchronous metastasis, recurrence, or leading to cancer-specific death. Expression levels of six genes (FOXC2, CLIP4, PBRM1, BAP1, SETD2, and KDM5C) were measured by reverse-transcription polymerase chain reaction (qRT-PCR) and their relation to clinical outcomes was investigated. Immunohistochemistry was performed to validate the expression profiles of selected genes significantly associated with clinical outcomes in multivariate analysis. Using these genes, we developed a prediction model of aggressive ccRCC based on logistic regression and deep-learning methods. FOXC2, PBRM1, and BAP1 expression levels were significantly lower in aggressive ccRCC than non-aggressive ccRCC both in univariate and multivariate analysis. The immunohistochemistry result demonstrated the significant downregulation of FOXC2, PBRM1, and BAP1 expression in aggressive ccRCC. Adding immunohistochemical staining results to qRT-PCR, the aggressive ccRCC prediction models had the area under the curve (AUC) of 0.760 and 0.796 and accuracy of 0.759 and 0.852 using the logistic regression method and deep-learning method, respectively. Use of these biomarkers and the developed prediction model can help stratify patients with clinical T1 stage ccRCC.

show abstract

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Cited by 516 publications

References 183 publications

Incidence of bone metastasis and factors contributing to its development and prognosis in newly diagnosed renal cell carcinoma: a population-based study

Incidence of bone metastasis and factors contributing to its development and prognosis in newly diagnosed renal cell carcinoma: a population-based study

Trends of Systemic Therapy Use for Renal Cell Carcinoma in the United States

Risk Prediction Tool for Aggressive Tumors in Clinical T1 Stage Clear Cell Renal Cell Carcinoma Using Molecular Biomarkers

Contact Info

Product

Resources

About